title: Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.
abstract: BACKGROUND
  Anti-CD20 monoclonal antibody treatment has not only increased survival and cure rates in many non-Hodgkin lymphomas, but also has prompted an explosion in the development of novel antibodies and biologically active substances with specific cellular targets in the field of malignancies treatment. Since the robust immune responses are elicited by the gene-modified T cells, gene based T cell therapy may also provide a powerful tool for cancer immunotherapy.
  
  
  METHODS
  In this study, we developed a vector construction encoding a chimeric T cell receptor that recognizes the CD20 antigen and delivers co-stimulatory signals to achieve T cell activation. One non-Hodgkin lymphoma cell line Raji cells co-cultured with peripheral blood-derived T cells were stably transfected with anti-CD20scFvFc/CD28/CD3zeta gene or anti-CD20scFvFc gene. T cells expressing anti-CD20scFvFc/CD28/CD3zeta or anti-CD20scFvFc gene co-cultured with CD20 positive Raji cells for different times. Cell lysis assay was carried by [3H]TdR release assay. The expressions of Fas, Bcl-2 and Caspase-3 of Raji cells were detected by flow cytometric. The secretion of IFN-gamma and IL-2 in co-culture medium was tested by ELISA assay. Activity of AP-1 was analyzed by EMSA.
  
  
  RESULTS
  Following efficient transduction of peripheral blood-derived T cells with anti-CD20scFvFc/CD28/CD3zeta gene, an obvious cell lysis of Raji cells was observed in co-culture. T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene had superior secretion of IFN-gamma and IL-2 compared to T cells transduced anti-CD20scFvFc gene. Also it led to a much stronger Fas-induced apoptosis signaling transduction in target cancer cells.
  
  
  CONCLUSIONS
  So adoptively T cells transduced anti-CD20scFvFc/CD28/CD3zeta gene mediates enhanced anti-tumor activities against CD20 positive tumor cells, suggesting a potential of gene-based immunotherapy for non-Hodgkin lymphoma.
authors.affiliation: Institute of Medical Research, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
authors.forename: Yihu
authors.initials: Y
authors.lastname: Zheng
authors.forename: Kang
authors.initials: K
authors.lastname: Yu
authors.forename: Jimei
authors.initials: J
authors.lastname: Du
authors.forename: Lei
authors.initials: L
authors.lastname: Jiang
authors.forename: Shenghui
authors.initials: S
authors.lastname: Zhang
authors.forename: Yixiang
authors.initials: Y
authors.lastname: Han
authors.forename: Panpan
authors.initials: P
authors.lastname: Yu
authors.forename: Yingxia
authors.initials: Y
authors.lastname: Tan
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics*; D018951:Antigens, CD20 / Q000276:immunology*; D018106:CD28 Antigens / Q000235:genetics*; D017252:CD3 Complex / Q000235:genetics*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D048430:Cell Shape; D018920:Coculture Techniques; D003602:Cytotoxicity, Immunologic; D024202:Electrophoretic Mobility Shift Assay; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D018808:Transcription Factor AP-1 / Q000378:metabolism; D014162:Transfection; D019014:fas Receptor / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D018106:CD28 Antigens; D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; C491901:FAS protein, human; C508594:IL2 protein, human; D007376:Interleukin-2; D019253:Proto-Oncogene Proteins c-bcl-2; D011993:Recombinant Fusion Proteins; D018808:Transcription Factor AP-1; D019014:fas Receptor; D007371:Interferon-gamma; C505407:CASP3 protein, human; D053148:Caspase 3
references.citation: J Immunol. 1983 Feb;130(2):988-92
references.pmid: 6294182
references.citation: J Immunol. 1989 Aug 15;143(4):1210-4
references.pmid: 2501391
references.citation: Cytotherapy. 2006;8(2):105-17
references.pmid: 16698684
references.citation: J Immunother. 2010 Feb-Mar;33(2):155-66
references.pmid: 20145548
references.citation: N Engl J Med. 2008 Nov 27;359(22):2313-23
references.pmid: 19038878
references.citation: J Exp Med. 1998 Aug 17;188(4):619-26
references.pmid: 9705944
references.citation: Leuk Lymphoma. 2008 Jul;49(7):1368-73
references.pmid: 18452062
references.citation: Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
references.pmid: 8421711
references.citation: Clin Cancer Res. 2000 Oct;6(10):3904-9
references.pmid: 11051236
references.citation: Neth J Med. 2009 Jul-Aug;67(7):251-9
references.pmid: 19687518
references.citation: Expert Opin Biol Ther. 2009 Nov;9(11):1407-25
references.pmid: 19723016
references.citation: Blood. 2002 Feb 1;99(3):1038-43
references.pmid: 11807010
references.citation: Nature. 2005 Jun 2;435(7042):677-81
references.pmid: 15902208
references.citation: Oncogene. 2003 Oct 20;22(47):7359-68
references.pmid: 14576843
references.citation: Blood. 2003 Jun 1;101(11):4279-84
references.pmid: 12576316
references.citation: Expert Opin Pharmacother. 2009 Apr;10(6):983-95
references.pmid: 19364248
references.citation: Clin Cancer Res. 2003 Jul;9(7):2487-96
references.pmid: 12855622